Scynexis INC 10-Q quarterly reports

SCYNEXIS, Inc. reports a net loss for the quarter but highlights a substantial capital raise and progress in its SCY-770 and SCY-247 development programs.

SCYNEXIS reported a wider net loss in Q3 2025, driven by reduced license revenue, while advancing its SCY-247 antifungal program and securing a $24.8 million payment from GSK following the termination of the MARIO study.

SCYNEXIS reported a significant reduction in net loss for Q2 2025, driven by a warrant liability fair value adjustment, while navigating a dispute with GSK over the MARIO study and a Nasdaq minimum bid price deficiency.

SCYNEXIS is in disagreement with GSK over the termination of the MARIO study for invasive candidiasis treatment, despite the FDA lifting the clinical hold.

SCYNEXIS reports its Q3 2024 financial results, impacted by a product recall and clinical hold, while also detailing ongoing legal proceedings and strategic updates.

SCYNEXIS, Inc. reported its second quarter 2024 financial results, which were significantly impacted by a product recall and clinical hold on its lead drug, ibrexafungerp, while also detailing ongoing legal proceedings and strategic adjustments.

SCYNEXIS reported its first quarter 2024 financial results, which were significantly impacted by a product recall and clinical hold related to its lead drug, ibrexafungerp.